Fairfield’s Competitive Technologies cut its losses by 28 percent in its second quarter, thanks to lower personnel costs and higher product sales, the company reported.
Product sales more than doubled in the quarter ended June 30, from $62,500 to $136,100, compared to the second quarter of 2012. That was due to higher sales of Calmare, a pain management device for which the company won a U.S. patent in February.
Competitive also cut its personnel and consulting costs in half to $278,700.
The company has exclusive worldwide rights to manufacture and sell the Calmare device, which is billed as a last-ditch solution for chronic pain sufferers who are all but resistant to anti-pain medication and implants.
The device uses electro-cutaneous nerve stimulation to interfere with the transmission of pain signals by mixing ”non-pain” information into the nerve fibers, a process developed in Italy and known as ‘Scrambler Therapy.’
